• About
  • Privacy Policy
  • Terms Of Use
  • Contact
Saturday, January 28, 2023
Pharma Info Nepal
  • Home
  • Loksewa
  • License
  • Questions
  • Vacancy
  • Downloads
  • Notice
No Result
View All Result
  • Home
  • Loksewa
  • License
  • Questions
  • Vacancy
  • Downloads
  • Notice
No Result
View All Result
Pharma Info Nepal
No Result
View All Result
Home Updates

DDA Approved COVISHIELD COVID-19 Vaccine for Emergency Use Authorization in Nepal 

DDA Approved COVISHIELD COVID-19 Vaccine for Emergency Use Authorization in Nepal 

Nabin Bista by Nabin Bista
January 28, 2021
in Updates
0
DDA Approved COVISHIELD COVID-19 Vaccine for Emergency Use Authorization in Nepal 
407
VIEWS
Share on FacebookShare on Twitter

DDA Approved COVISHIELD COVID-19 Vaccine for Emergency Use Authorization in Nepal

COVISHIELD COVID – 19  Vaccine has been Approved by DDA for Emergency Use Authorization of in Nepal

It is to notify to all concerned that the conditional permission has been granted for Emergency Use Authorization of COVISHIELD vaccine against COVID-19 in Nepal as per the departmental decision dated 15th Jan 2021.

DDA Approved COVISHIELD COVID-19 Vaccine for Emergency Use Authorization in Nepal prepared by Serum Institute of India Pvt. Ltd.

COVID-19 Vaccine AstraZeneca efficacy against COVID-19 is 95.85% 

At present, this vaccine is being administered to the leading health workers in Nepal by the Government of Nepal

WHAT IS COVID-19?
COVID-19 disease is caused by a coronavirus called SARS-CoV-2. This type of coronavirus has not been seen before. You can get COVID-19 through contact with another person who has the virus. It is predominantly a respiratory illness that can affect other organs. People with COVID-19 have had a wide range of symptoms reported, ranging from mild symptoms to severe illness. Symptoms may appear 2 to 14 days after exposure to the virus. Symptoms may include: fever or chills; cough; shortness of breath; fatigue; muscle or body aches; headache; new loss of taste or smell; sore throat; congestion or runny nose; nausea or vomiting; diarrhea.

WHAT IS THE SIIPL COVISHIELD™ VACCINE?
The COVISHIELD™ is approved for restricted use in emergency situation vaccine that may prevent COVID-19 disease in individuals 18 years of age and older.

WHAT SHOULD YOU MENTION TO YOUR HEALTHCARE PROVIDER BEFORE YOU GET COVISHIELD™ VACCINE?
Tell the healthcare provider about all of your medical conditions, including:

  • If you have ever had a severe allergic reaction (anaphylaxis) after any drug, food, any vaccine or any ingredients of COVISHIELD™ vaccine
  • If you have fever
  • If you have a bleeding disorder or are on a blood thinner
  • If you are immunocompromised or are on a medicine that affects your immune system
  • If you are breastfeeding
  • If you are pregnant or plan to become pregnant
  • If you have received another COVID-19 vaccine

You should consult your healthcare provider before deciding to take the vaccine.

WHO SHOULD NOT GET THE COVISHIELD™ VACCINE?
You should not get the COVISHIELD™ Vaccine if you:

  • had a severe allergic reaction after a previous dose of this vaccine
  • had a severe allergic reaction to any ingredient of this vaccine.

WHAT ARE THE INGREDIENTS IN THE COVISHIELD™ VACCINE?
The COVISHIELD™ Vaccine includes the following ingredients:
L-Histidine, L-Histidine hydrochloride monohydrate, Magnesium chloride hexahydrate, Polysorbate 80, Ethanol, Sucrose, Sodium chloride, Disodium edetate dihydrate (EDTA), Water for injection.

HOW IS THE COVISHIELD™ GIVEN?
The COVISHIELD™ Vaccine will be given to you as an intramuscular (IM) injection only, preferably in the deltoid muscle.
The COVISHIELD™ vaccination course consists of two separate doses of 0.5 ml each.

If you receive one dose of the COVISHIELD™ vaccine, then the second dose should be administered between 4 to 6 weeks after the first dose. However, there is data available for administration of the second dose up to 12 weeks after the first dose from the overseas studies.

If you miss your second dose
If you forget to go back at the scheduled time, ask your healthcare provider for advice. It is important that you return for your second dose of COVISHIELD™ vaccine.

HAS THE COVISHIELD™ VACCINE BEEN USED BEFORE?
The COVISHIELD™ is used in clinical trials, a number of participants received one or two doses in overseas and Indian trials.

WHAT ARE THE BENEFITS OF THE COVISHIELD™ VACCINE?
In ongoing clinical trials, the COVISHIELD™ Vaccine has been shown to prevent COVID-19 disease following 2 doses given between 4 and 12 weeks apart. The duration of protection against COVID-19 disease is currently unknown.
You may get protective immune response 4 weeks after the second dose of COVISHIELD™ vaccine.

WHAT ARE THE RISKS OF THE COVISHIELD™ VACCINE?
Side effects that have been reported with the COVISHIELD™ Vaccine include:
Very Common (may affect more than 1 in 10 people)

  • tenderness, pain, warmth, redness, itching, swelling or bruising where the injection is given
  • generally feeling unwell
  • feeling tired (fatigue)
  • chills or feeling feverish
  • headache
  • feeling sick (nausea)
  • joint pain or muscle ache
  • Common (may affect up to 1 in 10 people)
  • a lump at the injection site
  • fever
  • being sick (vomiting)
  • flu-like symptoms, such as high temperature, sore throat, runny nose, cough and chills

Uncommon (may affect up to 1 in 100 people)

  • feeling dizzy
  • decreased appetite
  • abdominal pain
  • enlarged lymph nodes
  • excessive sweating, itchy skin or rash

These may not be all the possible side effects of the COVISHIELD™ Vaccine. Serious and unexpected side effects may occur. COVISHIELD™ Vaccine is still being studied in clinical trials.

COVISHIELD COVID Vaccine has been Approved by DDA for Emergency Use Authorization of in Nepal
DDA Emergency Use Authorization of Covid – 19 Vaccine Permission Letter

  • Guidelines for Drug Donation to Nepal
  • Documents Required for New Drug, Industry Registration in Nepal
  • Instant Hand Sanitizer (Alcohol Based) Guideline Department of Drug Administration 
  • Department of Drug Administration Drug Recall Notice
Tags: DDAPharmacy Updates
Previous Post

Vacancy Announcement Pharmacy Lecturer Manmohan Memorial Institute of Health Sciences

Next Post

50 Important Pharmacy MCQs For Pharmacy Students 

Nabin Bista

Nabin Bista

Hello, Thank You for visiting my blog I am Nabin Bista, Dedicated and self motivated young Pharmacist from Nepal. Blogging is my passion. I am studying B Pharmacy at Institute of Medicine - IOM. If you want me to write about any posts that you found confusing/difficult, please mention in the comments below.

Related Posts

FDA-Approved HIV Medicines

FDA Approved HIV Medicines

January 26, 2023
Combined Oral Contraceptives (COC)

Combined Oral Contraceptives (COC)

January 17, 2023
Novel Drug Approvals for 2022

Novel Drug Approvals for 2022

January 3, 2023
B Pharmacy Entrance Exam Notice 2079

B Pharmacy Entrance Exam Notice 2079

January 2, 2023
Load More
Next Post
50 Important Pharmacy MCQs For Pharmacy Students 

50 Important Pharmacy MCQs For Pharmacy Students 

Discussion about this post

Recommended

Department of Drug Administration Drug Recall Notice

Department of Drug Administration Drug Recall Notice

2 years ago
Nepal Nursing Council 26th Name Registration Examination Notice

Nepal Nursing Council 26th Name Registration Examination Notice

2 years ago

Don't Miss

FDA-Approved HIV Medicines

FDA Approved HIV Medicines

January 26, 2023
Combined Oral Contraceptives (COC)

Combined Oral Contraceptives (COC)

January 17, 2023
Nepal Pharmacy Council 21st Name Registration Exam Application Form Notice

Nepal Pharmacy Council 21st Name Registration Exam Application Form Notice

January 9, 2023
Nepal Pharmacy Counci Notice

Nepal Pharmacy Council Notice

January 5, 2023

About Pharma Info Nepal

Pharma Info Nepal (Nabin’s Blog) was initiated in 2019 with the aim of providing relevant and accurate information for pharmacy, nursing and other health professionals. Since then it is conveying health related educational and informational updates of Nepal. It serves as a source for learning materials on diverse topics relating to medicine intended basically for pharmacy and nursing students. It covers job opportunities, question collections for pharmacy license, nursing license as well as various competitive exams.

Our readers rely on us for the well referenced and latest updates collected from the reliable sites.

Follow us

  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Instagram

Information Reader

Contents (text, image, graphics, documents and other materials) published on this portal are collected from other relevant sources with the sole purpose of sharing information. Contents and features are subject to change and all rights reserved to Pharma info Nepal. The information presented on this web portal and its official social media handles have no affiliation to any organization that author is involved with either professionally or personally.

If you have found anything displayed incorrectly or have further suggestions on improving our effort, please do not hesitate to reach out at pharmainfonepal1@gmail.com !
We hope you find Pharma info Nepal a helpful site. Thanks !!!

Categories

  • B Pharmacy
  • Colleges
  • D Pharmacy
  • Downloads
  • License
  • Loksewa
  • M Pharmacy
  • Medicinal Chemistry
  • Notice
  • Nursing
  • Pharmacognosy
  • Pharmacology
  • Questions
  • Scholarship
  • Study Materials
  • Syllabus
  • Updates
  • Vacancy

DOWNLOADS

Pharmacy Book 

Pharmacy Act and Guidelines

About Pharma Info Nepal

About Admin

  • About
  • Privacy Policy
  • Terms Of Use
  • Contact

© 2021 Nabin's Blog

No Result
View All Result
  • Home
  • Loksewa
  • License
  • Questions
  • Vacancy
  • Downloads
  • Notice

© 2021 Nabin's Blog

error: